Friday, 20 October 2017

Guhaprasad Nagarajan takes over as the CEO of Nirma owned ACULIFE

27 September 2017 | News

An alumnus of UDCT Mumbai, Mr. Guhaprasad is a B.Sc. Tech with a Masters in Management Studies (MMS) in Marketing from Somaiya Institute of Management and Research, Mumbai. With three decades of experience in the pharmaceutical industry, he has served in various capacities at some of the country’s top pharma organizations including Wockhardt, Alkem Laboratories and IPCA Laboratories.

Guhaprasad Nagarajan has taken over as the Chief Executive Officer (CEO) of Aculife Healthcare Pvt Ltd, a Nirma Group company. Aculife is a leader in intravenous fluids manufacturing with a product portfolio comprising of electrolytes, blood products, plasma volume expanders, specialised solutions like anaesthetics, parenteral nutrition and specialised antibiotics.

The USD 100mn company has 8 manufacturing plants and employs over 4000 employees with a presence in over 70 countries. As CEO Guhaprasad will institutionalise best practices into the entire value chain from product development to achieving leadership position in the markets that the company has its presence in. He also intends to leverage the organization’s excellent manufacturing infrastructure to penetrate into newer specialised portfolios.

Guhaprasad comes with a varied experience of over 30 years in building brands and teams by institutionalizing the brand, sales and team practices for reputed pharmaceutical companies in the global markets including India. In his last assignment as President (Global Brands and Global Institutional Business), he played a key role in aligning the R&D, Q.C., Q.A., and manufacturing and regulatory functions to achieve the best value for the organisation.

Aculife, a part of the Nirma group of companies has the world’s largest manufacturing infrastructure (spread over 650 acres) for parenteral solutions under one roof. This gives it the unique opportunity to leverage the same to become the leader in all the specialised parenteral solutions in its portfolio. This infrastructure will also be leveraged to enter into related and allied sterile solutions markets which offer significant opportunities in India as well as globally.

Guhaprasad has a penchant for a strong result oriented approach that is driven through institutionalising business processes. In the past he has built Mega Brands in the therapies of high-end Antibiotics, Cardiovascular, Pain, Antirheumatics, Anthelmintics and Antimalarials.

He has been credited with spearheading the presence of Alkem Laboratories in the high end antibiotics markets; Ipca Laboratories in Cardiovascular and Antidiabetic markets, and also successfully building its Global Brands and Global Institutional business in over 40 countries.

An alumnus of UDCT Mumbai, Mr Nagarajan is a B.Sc. Tech with a Masters in Management Studies (MMS) in Marketing from Somaiya Institute of Management and Research, Mumbai. With three decades of experience in the pharmaceutical industry, he has served in various capacities at some of the country’s top pharma organizations including Wockhardt, Alkem Laboratories and IPCA Laboratories.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is India becoming dependent on imports for key drug intermediates?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls